Anne Mette Plomgaard

Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial

Simon Hyttel-Sørensen, António Pellicer, Thomas Alderliesten et al. · BMJ · 2015 · 314 citations · Full text

Medicine, Neuroscience, Pediatrics +15

The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury

Anne Mette Plomgaard, Wim van Oeveren, Tue Hvass Petersen et al. · Pediatric Research · 2015 · 81 citations · Full text

Medicine, Neurology, Neuroscience +17

No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC <scp>II</scp>) in preterm infants during the first days of life

Anne Mette Plomgaard, Thomas Alderliesten, Frank van Bel et al. · Acta Paediatrica · 2018 · 63 citations · Full text

Medicine, Child Health, Pediatrics +17

Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial

Anne Mette Plomgaard, Thomas Alderliesten, Topun Austin et al. · PLoS ONE · 2017 · 62 citations · Full text

Medicine, Neuroscience, Pediatrics +13

Brain injury in the international multicenter randomized SafeBoosC phase II feasibility trial: cranial ultrasound and magnetic resonance imaging assessments

Anne Mette Plomgaard, Cornelia Hagmann, Thomas Alderliesten et al. · Pediatric Research · 2015 · 44 citations · Full text

Medicine, Neuroscience, Pediatrics +17